Research and Development
The partnership with Yissum Research Development Company of the Hebrew University (Yissum) is a key driver for R&D innovation and business growth.
Yissum has over 8,000 patents, more than 700 technology licences, and over 80 companies have been spun out from its research work. Products based on its technologies have generated over US$2 billion in sales and earned it a reputation as one of the world’s leading research and development and technology transfer companies.
Oral capsule formulation
The Company is implementing Yissum’s innovative nanoparticle formulation in its oral capsules, which contain the active cannabinoids THC and CBD for the treatment of Multiple Sclerosis.
The proprietary formulation is expected to overcome the effects of the ‘first pass’ metabolic effect of the cannabinoids in the gastrointestinal tract leading to significantly enhanced bioavailability of cannabinoids, addressing the currently inherent problem of very low bioavailability of cannabinoids when administered orally.
The product is anticipated to allow ease of administration, no side effects as ulcerations and pain, no adverse taste together with the high bioavailability capacity low cost and long room temperature shelf life.
Inner cheek Buccal patch
The company is developing, together with the Hebrew University team, a flexible, muco-adhesive inner cheek patch, which comprises of active cannabinoid ingredients. The patch will potentially provide continuous delivery of THC and CBD for 4-6 hours. The ingredients are transferred through the mucous membrane in the cheek directly into the systemic blood circulation avoiding the digestive system. The product is anticipated to allow for better dose control, easy application, no adverse taste and cost effectiveness.